The dolabellane diterpene Dolabelladienetriol is a typical noncompetitive inhibitor of HIV-1 reverse transcriptase enzyme

Antiviral Research

Volumn 77, Issue 1, 2008, Pages 64-71

  Cirne Santos, Claudio Cesar ^a   Souza, Thiago Moreno L ^a,c,d   Teixeira, Valéria L ^b   Fontes, Carlos Frederico L ^c   Rebello, Moacyr A ^c   Castello Branco, Luiz Roberto R ^a   Abreu, Celina M ^c   Tanuri, Amílcar ^c   Frugulhetti, Izabel C P P ^d   Bou Habib, Dumith Chequer ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Instituto de Biologia   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

AIDS; Diterpene; Dolabelladienetriol; HIV 1; Reverse transcriptase

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DITERPENE; DOLABELLADIENETRIOL; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFECT; DRUG ISOLATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROVIRUS; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DITERPENES; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; KINETICS; LEUKOCYTES, MONONUCLEAR; MUTATION; PROVIRUSES; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS INTEGRATION;

ALGAE; DICTYOTA PFAFFII; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 37549017330     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.08.006     Document Type: Article

References (32)

1. Alakurtti S., Makela T., Koskimies S., and Yli-Kauhaluoma J. Pharmacological properties of the ubiquitous natural product betulin. Eur. J. Pharm. Sci. 29 (2006) 1-13
2. Arts E.J., Mak J., Kleiman L., and Wainberg M.A. Mature reverse transcriptase (p66/p51) is responsible for low levels of viral DNA found in human immunodeficiency virus type 1 (HIV-1). Leukemia 8 Suppl. 1 (1994) S175-S178
3. Arts E.J., and Wainberg M.A. Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription. Adv. Virus Res. 46 (1996) 97-163
4. Balunas M.J., and Kinghorn A.D. Drug discovery from medicinal plants. Life Sci. 78 (2005) 431-441
5. Barbosa J.P., Pereira R.C., Abrantes J.L., Cirne dos Santos C.C., Rebello M.A., Frugulhetti I.C., and Texeira V.L. In vitro antiviral diterpenes from the Brazilian brown alga Dictyota pfaffii. Planta Med. 70 (2004) 856-860
6. Cirne-Santos C.C., Teixeira V.L., Castello-Branco L.R., Frugulhetti I.C., and Bou-Habib D.C. Inhibition of HIV-1 replication in human primary cells by a dolabellane diterpene isolated from the marine algae Dictyota pfaffii. Planta Med. 72 (2006) 295-299
7. Clotet B. Efavirenz: resistance and cross-resistance. Int. J. Clin. Pract. Suppl. 103 (1999) 21-25
8. Deeks S.G. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 26 Suppl. 1 (2001) S25-S33
9. De Lucca G.V., Liang J., Aldrich P.E., Calabrese J., Cordova B., Klabe R.M., Rayner M.M., and Chang C.H. Design, synthesis, and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors. J. Med. Chem. 40 (1997) 1707-1709
10. de Souza Pereira H., Leäo-Ferreira L.R., Moussatché N., Teixeira V.L., Cavalcanti D.N., da Costa L.J., Diaz R., and Frugulhetti I.C. Effects of diterpenes isolated from the Brazilian marine alga Dictyota menstrualis on HIV-1 reverse transcriptase. Planta Med. 71 (2005) 1019-1024
11. Dukes C.S., Matthews T.J., Lambert D.M., Dreyer G.B., Petteway S.R., and Weinberg J.B. Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates. AIDS Res. Hum. Retroviruses 12 (1996) 777-782
12. Hazen R.J., Harvey R.J., St Clair M.H., Ferris R.G., Freeman G.A., Tidwell J.H., Schaller L.T., Cowan J.R., Short S.A., Romines K.R., Chan J.H., and Boone L.R. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance. Antimicrob. Agents Chemother. 49 (2005) 4465-4473
13. Hirsch M.S., Brun-Vezinet F., D'Aquila R.T., Hammer S.M., Johnson V.A., Kuritzkes D.R., Loveday C., Mellors J.W., Clotet B., Conway B., Demeter L.M., Vella S., Jacobsen D.M., and Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 283 (2000) 2417-2426
14. Hottiger M., and Hübscher U. Human Immunodeficiency Virus type 1 reverse transcriptase. Biol. Chem. Hoppe Seyler 377 (1996) 97-120
15. Ingarro L.J., Ayala C., and Spellberg B. Medical/Nursing (2003), Blackwell Publishing, UK, Oxford Chapter 1, pp. 1-11
16. Lima R.G., Van Weyenbergh J., Saraiva E.M., Barral-Netto M., Galväo-Castro B., and Bou-Habib D.C. The replication of human immunodeficiency virus type 1 in macrophages is enhanced after phagocytosis of apoptotic cells. J. Infect. Dis. 185 (2002) 1561-1566
17. Maga G., Ubiali D., Salvetti R., Pregnolato M., and Spadari S. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes. Antimicrob. Agents Chemother. 44 (2000) 1186-1194
18. Marquez N., Sancho R., Bedoya L.M., Alcami J., López-Pérez J.L., Feliciano A.S., Fiebich B.L., and Munoz E. Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kappaB pathway. Antiviral Res. 66 (2005) 137-145
19. Matthée G., Wright A.D., and König G.M. HIV reverse transcriptase inhibitors of natural origin. Planta Med. 65 (1999) 493-506
20. Meyer P.R., Smith A.J., Matsuura S.E., and Scott W.A. Effects of primer-template sequence on ATP-dependent removal of chain-terminating nucleotide analogues by HIV-1 reverse transcriptase. J. Biol. Chem. 279 (2004) 45389-45398
21. Odriozola L., Cruchaga C., Andréola M., Dollé V., Nguyen C.H., Tarrago-Litvak L., Pérez-Mediavilla A., and Martinez-Irujo J.J. Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3'-azido-3'-deoxythymidine (AZT)-resistant polymerase to AZT-5'-triphosphate. J. Biol. Chem. 278 (2003) 42710-42716
22. Pereira H.S., Leäo-Ferreira L.R., Moussatché N., Teixeira V.L., Cavalcanti D.N., Costa L.J., Diaz R., and Frugulhetti I.C. Antiviral activity of diterpenes isolated from the Brazilian marine alga Dictyota menstrualis against human immunodeficiency virus type 1 (HIV-1). Antiviral Res. 64 (2004) 69-76
23. Pomerantz R.J., and Horn D.L. Twenty years of therapy for HIV-1 infection. Nat. Med. 9 (2003) 867-873
24. Robinson B.S., Riccardi K.A., Gong Y.F., Guo Q., Stock D.A., Blair W.S., Terry B.J., Deminie C.A., Djang F., Colonno R.J., and Lin P.F. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44 (2000) 2093-2099
25. Rodríguez-Arenas M.A., Jarrin I., del Amo J., Iribarren J.A., Moreno S., Viciana P., Pena A., Sirvent J.L., Vidal F., Lacruz J., Gutierrez F., Oteo J.A., Asencio R., Castilla J., and Hoyos S.P. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res. Hum. Retroviruses 22 (2006) 715-723
26. Sabin C.A., Smith C.J., Youle M., Lampe F.C., Bell D.R., Puradiredja D., Lipman M.C., Bhagani S., Phillips A.N., and Johnson M.A. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 20 (2006) 67-71
27. Sluis-Cremer N., Temiz N.A., and Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr. HIV Res. 2 (2004) 323-332
28. Snyder S., D'Argenio D.Z., Weislow O., Bilello J.A., and Drusano G.L. The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob. Agents Chemother. 44 (2000) 1051-1058
29. Sobanski T., Assion H.J., Scholl H.P., Höflich G., and Laux G. Successful zidovudine (AZT) treatment in a case of human immunodeficiency virus (HIV)-1-associated dementia complex. Biol. Psychiatry 39 (1996) 1065-1066
30. Stebbing J., Bower M., Mandalia S., Nelson M., and Gazzard B. Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality. Clin. Exp. Immunol. 145 (2006) 271-276
31. Stuyver L., Wyseur A., Rombout A., Louwagie J., Scarcez T., Verhofstede C., Rimland D., Schinazi R.F., and Rossau R. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob. Agents Chemother. 41 (1997) 284-291
32. Zhang Z., Walker M., Xu W., Shim J.H., Girardet J.L., Hamatake R.K., and Hong Z. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 50 (2006) 2772-2781